Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.16, Iss.8, 2013-08, pp. : 1082-1088

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐acting muscarinic antagonist + long‐acting beta agonist versus long‐acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta‐analysis

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 8, 2015-11 ,pp. : 1153-1159

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 245-250

Bentham Science Publishers

Access to resources Recommend Favorite

Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer

Urologia Internationalis, Vol. 77, Iss. 2, 2006-08 ,pp. : 135-138

Karger

Access to resources Recommend Favorite

Effects of Long‐Acting Versus Short‐Acting Calcium Channel Blockers Among Older Survivors of Acute Myocardial Infarction

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 47, Iss. 5, 1999-05 ,pp. : 512-517

John Wiley & Sons Inc

Access to resources Recommend Favorite

Indacaterol, a novel inhaled, once-daily, long-acting beta 2 -agonist for the treatment of obstructive airways diseases

By Beeh Kai

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 691-699

Springer Publishing Company

Access to resources Recommend Favorite